News|Articles|November 17, 2026

Full X-TOLE2 Data Detail Azetukalner's Dose-Dependent Profile in Focal Epilepsy

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • X-TOLE2 enrolled a globally representative, drug-resistant population (median five prior ASMs; ~13 seizures/28 days) and demonstrated rapid, durable efficacy over a 12-week double-blind period.
  • Median monthly focal seizure reduction reached 53.2% (25 mg) and 34.5% (15 mg) versus 10.4% with placebo, with ≥50% responder rates of 54.8% and 37.6%.
SHOW MORE

Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.

Newly published in JAMA Neurology, the complete phase 3 X-TOLE2 results offer the clearest look yet at how azetukalner (Xenon Pharmaceuticals), a Kv7 potassium channel opener now under FDA review, performs in adults with focal seizures. The peer-reviewed paper also filled in the safety picture behind the topline efficacy numbers Xenon Pharmaceuticals reported earlier this year, detailing how side effects differ between the drug's two tested doses.1

The trial (NCT05614063), led by Jacqueline A. French, MD, of NYU Langone Health, who chairs the X-TOLE2 steering committee, randomized 374 adults with drug-resistant focal epilepsy, 1:1:1, to placebo, azetukalner 15 mg, or azetukalner 25 mg, once daily with no titration, across 138 sites in North America, Europe, Latin America, and Asia Pacific. Participants had tried a median of 5 prior antiseizure medications and averaged about 13 focal seizures per 28 days at baseline, following an 8-to-9.5-week baseline period and a 12-week double-blind treatment period.

On the primary endpoint, median monthly focal seizure frequency fell 53.2% with 25 mg and 34.5% with 15 mg, compared with 10.4% with placebo (P <.001 for both doses). At least a 50% reduction in seizures was achieved by 54.8% of patients on 25 mg and 37.6% on 15 mg, versus 20.8% on placebo. On a patient-reported global impression of change, 45.2% (25 mg) and 46.4% (15 mg) of patients rated themselves "much improved" or better, compared with 26.4% on placebo.

Adverse events rose with dose: at least 1 treatment-emergent adverse event occurred in 82.3% of patients on 25 mg, 67.2% on 15 mg, and 62.4% on placebo, and discontinuation due to adverse events was more than 4 times as common on 25 mg (14.5%) as on 15 mg (4.8%) or placebo (3.2%). No deaths were reported.[1] Several specific effects were markedly more frequent at the higher dose, including dizziness (31.5% vs 3.2% on placebo), confusional state (10.5% vs 0.8%), aphasia (9.7% vs none on placebo), gait disturbance (9.7% vs none), and tremor (12.1% vs 1.6%).1

READ MORE: Cenobamate sNDA Seeks FDA Approval for Generalized Seizures

“Azetukalner demonstrated robust, rapid, and durable reductions in seizure frequency with a favorable benefit-risk profile,” French and her coauthors wrote, describing the 25-mg effect as “one of the largest median percentage reductions in seizure frequency vs placebo reported to date in patients with drug-resistant epilepsy.”1 After Xenon first reported the topline data, French said the results “reinforce the value that azetukalner and its KV7 mechanism may bring” to a field with few distinct mechanisms of action.

From phase 2b to a pending FDA decision

Xenon submitted a new drug application to the FDA for azetukalner in September 2026, built on X-TOLE2 together with the earlier phase 2b X-TOLE trial. If approved, azetukalner would become the first Kv7 (KCNQ2/3) potassium channel opener available for epilepsy. An earlier drug with the same mechanism, ezogabine, was discontinued after reports of blue-gray skin and eye discoloration; no treatment-emergent tissue discoloration has been reported across azetukalner's development program.2

Phase 2b X-TOLE, published in JAMA Neurology in 2023, had already shown median seizure-frequency reductions of 52.8% at 25 mg, 46.4% at 20 mg, and 33.2% at 10 mg, versus 18.2% with placebo.2 In its open-label extension, data presented at the 2025 American Epilepsy Society meeting showed 20.7% of participants reaching at least 1 year of seizure freedom, and 10% remaining seizure-free for 48 months or longer, in a population that Xenon's chief medical officer, Christopher Kenney, MD, described in an earlier interview as “the most impaired FOS population ever assembled for a trial.”

The newly published X-TOLE2 data put firmer numbers behind that record, and behind its tradeoffs. The 25-mg dose produced the largest seizure reductions in both X-TOLE studies, but it also drove most of the program's discontinuations and its dose-related neurological and psychiatric adverse events, a tradeoff regulators and prescribers will now weigh directly as azetukalner's NDA moves through FDA review.

REFERENCES
1. French JA, LaFrance WC Jr, Ryvlin P, et al. Azetukalner in adults with focal seizures: the X-TOLE2 phase 3 randomized clinical trial. JAMA Neurol. Published online November 9, 2026. doi:10.1001/jamaneurol.2026.4141
2. French JA, Porter RJ, Perucca E, et al. Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: a phase 2b randomized clinical trial. JAMA Neurol. 2023;80(11):1145-1154. doi:10.1001/jamaneurol.2023.3542

Related to this article